Daewoong Pharmaceutical Completes Patient Enrollment for Global Phase 2 IPF Trial of Fibrosis Treatment Candidate Bersiporocin
Daewoong Pharmaceutical announced on May 6 that it has completed patient enrollment for the global Phase 2 clinical trial (NCT05389215) of its idiopathic pulmonary fibrosis (IPF) treatment candidate, bersiporocin (DWN12088).
Researchers at Daewoong Pharmaceutical conducting a study. Daewoong Pharmaceutical
View original imageThe company explained that the completion of patient enrollment marks a significant milestone, demonstrating that the global clinical development of bersiporocin is progressing smoothly and laying the groundwork for accelerating discussions on potential global technology licensing deals in the future.
The clinical trial is currently underway in both Korea and the United States, evaluating the safety, tolerability, and efficacy of bersiporocin both as a monotherapy and in combination with existing antifibrotic drugs (nintedanib and pirfenidone).
Daewoong Pharmaceutical has been building scientific evidence by presenting the study design and patient characteristic analysis results of the global Phase 2 trial at major academic conferences. The company is validating the potential of bersiporocin in patient groups that reflect real-world clinical settings.
Based on the results of the global Phase 2 trial, which are expected in the first quarter of 2027, Daewoong Pharmaceutical plans to focus on global partnerships and out-licensing opportunities. In the mid- to long-term, the company aims to expand its fibrosis treatment portfolio through the development of various formulations and indications.
Bersiporocin is a first-in-class innovative drug candidate that selectively inhibits prolyl-tRNA synthetase (PRS), a key enzyme involved in collagen synthesis, thereby targeting the root cause of fibrosis. The compound was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019, selected for the FDA’s Fast Track program in 2022, and also received orphan drug designation from the European Medicines Agency (EMA).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Seongsu Park, CEO of Daewoong Pharmaceutical, stated, "The completion of patient enrollment for the global Phase 2 IPF trial is a pivotal turning point for the development of bersiporocin. We will do our utmost to enhance the commercial potential of bersiporocin based on global clinical data and to provide new treatment options to patients worldwide through global partnerships."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.